Emcure Pharmaceuticals

Emcure Pharmaceuticals

Company type	Public
Traded as	BSE: 544210 NSE: EMCURE
Industry	Pharmaceuticals
Founded	April 15, 1981 (1981-04-15)
Founder	Satish Ramanlal Mehta
Headquarters	Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, Maharashtra , India
Area served	Worldwide
Key people	Satish Ramanlal Mehta (CEO & MD) Namita Thapar (Whole Time Director) Sunil Rajanikant Mehta (Whole Time Director) Samit Satish Mehta (Whole Time Director) Berjis Minoo Desai (Chairman)
Products	Tablets, capsules, injectables, biotherapeutics, active pharmaceutical ingredients (APIs)
Revenue	₹7,896 crore (FY 2025)
Net income	₹707 crore (FY 2025)
Number of employees	6733 (January 2025)
Website	www.emcure.com

Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Established in 1981, it develops, manufactures, and markets a wide range of pharmaceutical products, including generics, biotherapeutics, and active pharmaceutical ingredients (APIs) across therapeutic areas such as gynaecology, cardiology, oncology, HIV, and blood-related disorders. The company operates in over 70 countries, with a strong presence in India, Europe, and Canada. Emcure is recognised as the 12th largest pharmaceutical company in India by domestic sales (AIOCD-AWACS, June 2024) and is known for its research-driven approach, with approximately 500 scientists contributing to its innovation pipeline. In 2024, Emcure launched its initial public offering (IPO), listing on the BSE and NSE.

Founders & Leadership

Emcure Pharmaceuticals was founded by Satish Ramanlal Mehta, who serves as the CEO and Managing Director. Mehta, a postgraduate in Chemistry from Pune University and a diploma holder in management from IIM Ahmedabad, started Emcure with a ₹3 lakh bank loan in 1981. His leadership transformed the company from a contract manufacturer to a global player in generics and biotherapeutics. Notable achievements include establishing Emcure as a leader in gynaecology and HIV antivirals in India and forging partnerships with global pharmaceutical companies like Bristol-Myers Squibb and Roche. The leadership team includes Namita Thapar (Whole Time Director), Sunil Rajanikant Mehta (Whole Time Director), Samit Satish Mehta (Whole Time Director), and Berjis Minoo Desai (Chairman).

Origin & Founding Story

File:Namita Thapar Emcure.jpg

Namita Thapar, the Executive director of Emcure Pharmaceuticals

Emcure Pharmaceuticals was founded in 1981 by Satish Ramanlal Mehta in Pune, Maharashtra. Starting as a contract manufacturer for multinational pharmaceutical companies, Mehta leveraged his education from IIM Ahmedabad and family business background to pivot Emcure towards developing branded generic formulations. With an initial bank loan of ₹3 lakh, Mehta built a company focused on innovation, particularly in complex APIs and biotherapeutics. By the 1990s, Emcure transitioned into producing generics, and by 2006, it secured licensing agreements with global giants like Bristol-Myers Squibb and Gilead Sciences. The company’s emphasis on research and development, coupled with strategic partnerships, enabled its expansion into over 70 countries.

Timeline

Year	Milestone
1981	Emcure Pharmaceuticals founded by Satish Ramanlal Mehta in Pune with a ₹3 lakh bank loan.
1990s	Transitioned from contract manufacturing to producing generic drugs.
2006	Signed licensing agreements with Bristol-Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir.
2006	Received US FDA approval for solid dosage facility at Hinjawadi, Pune.
2012	Signed agreement with Roche to manufacture anticancer drugs Herceptin and Mabthera in India.
2013	Launched health foods venture in partnership with cricketer MS Dhoni.
2014	Bain Capital acquired 13% stake from Blackstone.
2021	Demerged US-based business into Avet Lifesciences.
2024	Launched IPO, raising $234 million, listed on BSE and NSE.
2025	Incorporated wholly-owned subsidiary Emcure Generics Private Limited.

Funding

Date	Round	Amount	Investors
2006	Private Equity	Undisclosed	Blackstone
2014	Private Equity	Undisclosed	Bain Capital (acquired 13% stake from Blackstone)
2024	IPO	$234 million	Public investors

Business Model

Emcure Pharmaceuticals operates a diversified business model, generating revenue through the development, manufacturing, and global marketing of pharmaceutical products. Its primary customer segments include healthcare providers, hospitals, and retail pharmacies in India and over 70 countries, with key markets in Europe, Canada, and the Rest of the World (RoW). The company focuses on generics, biotherapeutics, and complex APIs, leveraging its research and development capabilities to launch differentiated products. Approximately 46.84% of its FY 2023 revenue came from international markets, with 30% from regulated markets like Canada and Europe, and the rest from contract manufacturing and other segments. Emcure also engages in strategic partnerships with multinational corporations for in-licensing and technology transfers, enhancing its product portfolio and market reach.

Products / Services

Emcure Pharmaceuticals offers a diverse portfolio of pharmaceutical products across multiple therapeutic areas:

• Tablets and Capsules: Includes oral solids and liquids for gynaecology, cardiology, oncology, HIV, and anti-infectives. Notable brands include Maxtra, Metpure, and Asomex.
• Injectables: Includes liposomal and lyophilised injectables, such as Elaxim and Hamsyl, used in cardiology and oncology.
• Biotherapeutics: Through its subsidiary Gennova Biopharmaceuticals, Emcure has launched six biologics, including Elaxim, Tenectase, and Vintor, focusing on cardiology, nephrology, and oncology.
• Active Pharmaceutical Ingredients (APIs): Manufactures complex APIs, including chiral molecules and cytotoxic products.
• Health Foods: Launched a venture in 2013 with MS Dhoni to offer nutritional products.

Growth & Metrics

Emcure Pharmaceuticals has demonstrated significant growth, with a trailing 12-month revenue of $893 million (approximately ₹7896 crore) and a net profit of ₹707 crore in FY 2025. The company reported a 19.5% year-on-year revenue increase to ₹2116 crore in Q4 FY 2025, with a 63% rise in net profit to ₹197 crore. Its market capitalisation stands at ₹24,337 crore as of May 2025. Emcure employs 6733 people (January 2025) and has a global presence in over 70 countries, with 350+ brands and 13 manufacturing facilities in India. The company’s domestic business grew by 12% in Q3 FY 2025, while international sales surged by 25%.

Legal Entity Information

Field	Details
Legal Name	Emcure Pharmaceuticals Limited
Foundation Date	15 April 1981
Registrar of Companies	ROC Pune
Corporate Identification Number (CIN)	U24231PN1981PLC024251
Registered Address	Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, Maharashtra 411057
Email ID	investors@emcure.com
Company Status	Active
Directors	Berjis Minoo Desai Satish Ramanlal Mehta Sunil Rajanikant Mehta Namita Vikas Thapar Samit Satish Mehta 2 others
Authorized Share Capital	₹2,000,000,000
Paid-up Capital	₹1,808,521,160

Acquisitions and Investments

• Demerger: In 2021, Emcure demerged its US-based business, including subsidiary Heritage Pharmaceuticals, into Avet Lifesciences.
• Investment: In 2025, an Emcure executive participated in a $3 million investment round for Medulance, a healthcare startup.
• Subsidiary Formation: In May 2025, Emcure incorporated Emcure Generics Private Limited, a wholly-owned subsidiary focused on manufacturing and distributing pharmaceuticals.

Media & Public Recognition

Emcure Pharmaceuticals has received significant recognition for its contributions to the pharmaceutical industry. It was ranked the 12th largest pharmaceutical company in India by domestic sales (AIOCD-AWACS, June 2024). The company’s IPO in 2024, raising $234 million, drew $11 billion in bids, reflecting strong market confidence. Emcure’s executive Namita Thapar gained public attention as a judge on Shark Tank India, advocating for work-life balance. However, the company faced scrutiny for a 2016 US FDA warning letter regarding data integrity issues and a 2019 DOJ settlement involving its former subsidiary Heritage Pharmaceuticals.

FAQs

What is Emcure Pharmaceuticals known for?

Emcure is known for developing, manufacturing, and marketing generics, biotherapeutics, and APIs across therapeutic areas like gynaecology, cardiology, oncology, and HIV.

Where does Emcure operate?

The company operates in over 70 countries, with key markets in India, Europe, Canada, and the Rest of the World (RoW).

What was the purpose of Emcure’s 2024 IPO?

The IPO raised $234 million to fund debt repayment and corporate purposes, strengthening its financial position.

Who founded Emcure Pharmaceuticals?

Emcure was founded by Satish Ramanlal Mehta in 1981, who remains the CEO and Managing Director.

External Links

• Official website
• LinkedIn
• X (Twitter)
• Facebook

Related Startups

• Sun Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Cipla
• Glenmark Pharmaceuticals
• Lupin Limited